Publication of Mineral Resource Estimate for Storeknuten in the Høyland Exploration Area
4.5.2021 09:55:00 EEST | Business Wire | Press release
Norge Mining plc, the Anglo-Norwegian mineral exploration company focused on the Bjerkreim Exploration Project in southwest Norway, announces publication of a Mineral Resource Estimate for the Storeknuten Deposit in the Høyland Exploration Area. The data confirms Storeknuten as the Company’s second world-class discovery in the Bjerkreim Exploration Project.
The Storeknuten Mineral Resource covers an area of about 400,000 sq m, which represents approximately 15% of the Høyland Exploration Area.
Publication of the Storeknuten Mineral Resource Estimate follows publication in February this year of the maiden Mineral Resource Estimate at Øygrei, a world-class deposit of 1.55 billion tonnes which is currently being extended and upgraded.
Highlights
- Maiden Mineral Resource Estimate reported for Storeknuten of 240 million tonnes, containing mean grades of 2.36% phosphorus pentoxide, 4.71% titanium dioxide and 0.07% vanadium pentoxide.
- Storeknuten is the Company’s second world-class resource of EU Critical Raw Materials, defined as materials of strategic importance for the European economy that the EU currently imports.
- The Mineral Resource Estimate at Storeknuten was prepared according to the JORC2 reporting standard by SRK Exploration Services Ltd (SRK), part of the SRK Group, which is an independent international mining, exploration and environmental consultant.
- The Storeknuten Mineral Resource Estimate is summarised below:
|
Mineral Resource Classification |
Tonnes
|
P2O5 Grade
|
TiO2 Grade
|
V2O5 Grade
|
|
Inferred |
240.0 |
2.36 |
4.71 |
0.07 |
|
Total |
240.0 |
2.36 |
4.71 |
0.07 |
- The higher phosphate grade of this deposit opens up potential opportunities for alternative mining and processing scenarios.
- Exploration work at Storeknuten is ongoing firstly to extend the resource and then in due course to improve confidence in the estimate with the aim of upgrading a portion of the resource to the Indicated category.
John Vergopoulos, Chief Executive Officer of Norge Mining, said:
“This Mineral Resource Estimate confirms Storeknuten as our second world-class deposit, further highlighting the potential of the Bjerkreim Exploration Project as a whole. In addition to 240 million tonnes of Inferred Mineral Resource at Storeknuten, SRK has also reported a very substantial Exploration Target of between 1.4 and 2.0 billion tonnes."
“Given the constraints of Covid-19 on exploration work at Storeknuten during the past year, I am particularly pleased by this initial Mineral Resource Estimate."
“Together with Øygrei, whose world-class status was established earlier this year, we now have a total Mineral Resource Estimate at Bjerkreim of 1.79 billion tonnes and an Exploration Target of between 2.4 and 4.0 billion tonnes, all containing vanadium, titanium and phosphate."
“These three minerals are on the EU’s list of Critical Raw Materials, giving Norway a major opportunity to play a pivotal strategic role in the future supply of these materials."
“Exploration work is ongoing to upgrade and extend the resource at both Storeknuten and Øygrei. We also continue to drill in other areas and expect to announce further data in the coming months.”
An executive summary of the Storeknuten Mineral Resource Estimate is available at the Company’s website: www.norgemining.com
Background to the Bjerkreim Exploration Project
The Bjerkreim Exploration Project is located in southwest Norway in the large Bjerkreim-Sokndal Layered Intrusion, which has been widely studied by the Norway Geological Survey (NGU) and other researchers. Norge Mining is focusing on the Bjerkreim Lobe of this intrusion, which forms a large synclinal trough structure. This trough extends at outcrop for some 20km northwest-southeast and up to 10km northeast-southwest. It is known to extend for several kilometres in depth.
The mineralisation consists of primary magmatic mineral assemblages in which vanadium-bearing magnetite, ilmenite (titanium) and apatite (phosphate) represent the minerals of interest. Vanadium, titanium and phosphate are all on the EU’s list of Critical Raw Materials, defined as materials of strategic importance for the European economy that the EU currently imports.
Through its Norwegian subsidiary Norge Mineraler AS, Norge Mining has 46 exploration licences in southwest Norway, totalling more than 400 sq km. The Company has conducted extensive ongoing exploration work at Bjerkreim, including channel sampling, aerial surveys and shallow and deep drilling. In total, more than 30,000m of drilling has now been completed.
Storeknuten forms part of the Høyland Exploration Area in the Bjerkreim Exploration Project. It covers an area of 1,150m by 350m and is located 4.5km southwest from the Company’s Øygrei Deposit.
SRK Exploration Services Ltd (SRK), part of the SRK Group, an international mining, exploration and environmental consultant, has prepared the Mineral Resource Estimate at Storeknuten. The diamond drilling programme at Storeknuten began in September 2020 and the data cut-off used to produce the resource estimate was 1 March 2021. The data for resource estimation was derived from 1,437 assayed samples from 9 drill holes.
Storeknuten Mineral Resource Estimate
SRK’s maiden Mineral Resource Estimate for the Storeknuten area of the Bjerkreim Exploration Project, reported according to the JORC Code reporting standard, is summarised below:
|
Mineral Resource Classification |
Tonnes
|
P2O5 Grade
|
TiO2 Grade
|
V2O5 Grade
|
|
Inferred |
240.0 |
2.36 |
4.71 |
0.07 |
|
Total |
240.0 |
2.36 |
4.71 |
0.07 |
As is the case at Øygrei, the mineralisation occurs in steep dipping layers that are continuous down dip and along strike. The vast majority of the reported Mineral Resource correlates to the B Zone previously reported on at Øygrei and, while it does contain a small amount of C Zone, it does not contain any New Zone and consequently the P2O5 grades are higher.
In reporting a Mineral Resource, there is a requirement that there are reasonable prospects for eventual economic extraction. In this case, the requirement has been achieved by limiting the tonnage reported to that falling within an open pit which was optimised assuming selling prices of USD230/t of ilmenite, USD97.75/t of phosphate and USD9.2/lb of V2O5.
Storeknuten Exploration Target
SRK has delineated a Storeknuten Exploration Target, also as defined by the JORC Code, of between 1.4 and 2.0 billion tonnes of mineralisation with similar grades to that already reported (between 1.6 and 2.4% P2O5, 4.2 and 5.0% TiO2 and 0.06 and 0.08% V2O5).
This Exploration Target is based on the assumed continuity of the mineralised layers at Storeknuten at depth and to the northeast. Surface geology supports this continuity, and the mineralisation drilled to date remains open in these directions. It should however be noted that the Exploration Target potential tonnage and grade estimates are conceptual in nature, that there has been insufficient exploration to estimate a Mineral Resource and that it is uncertain if further exploration will result in the estimation of a Mineral Resource.
Next Steps
Exploration work at Storeknuten is ongoing with a substantial, planned programme of additional drilling to upgrade and extend the Mineral Resource and to provide information for a scoping study. The drilling work is expected to be completed this year.
Exploration work at Øygrei, and elsewhere in the Bjerkreim Exploration Project including Skeipstad, is also ongoing. At Øygrei more than 13,000m of infill and geotechnical drilling is underway, part of the aim of which is to increase confidence in the Mineral Resource and enable more to be reported in the Indicated category.
1 World-class deposit is used in the context of this announcement to mean a deposit of very large size with the potential to provide major economic and strategic benefits.
2 The reporting standard for this statement is the 2012 edition of the “Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves” as published by the Joint Ore Reserves Committee of the Australasian Institute of Mining and Metallurgy, Australian Institute of Geoscientists and Minerals Council of Australia” (the “JORC Code”). The JORC Code is a reporting code which has been aligned with the Committee for Mineral Reserves International Reporting Standards (“CRIRSCO”) reporting template and is an internationally recognised reporting standard that has been adopted worldwide for market-related reporting and financial investments.
The Competent Person who has overall responsibility for the Mineral Resource is Dr Mike Armitage, C.Eng, C. Geol, FGS, MIMM, PhD. Dr Armitage is a Chartered Geologist which is a Recognised Professional Organisation (“RPO”) included in a list promulgated by the Australian Securities Exchange (“ASX”) from time to time. He is a full time employee of SRK Consulting (UK) Ltd and a director of SRK Exploration Services, a corporate consultant and has over 35 years’ experience in the mining and metals industry and also has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity which he is undertaking to qualify as a Competent Person as defined in the JORC Code. Dr Armitage has been responsible for the reporting of Mineral Resources and Ore Reserves on various properties internationally during the past 30 years.
About Norge Mining plc
Norge Mining plc is an Anglo-Norwegian natural resources company focused on mineral exploration in Norway.
The Company owns 46 exploration licences, totalling more than 400 square kilometres in south-west Norway in an area known to contain vanadium, titanium, phosphate and gold. Norge Mining is currently conducting a programme of exploration work to produce a resource estimate, building on earlier studies by the Norway Geological Survey (NGU).
Norge Mining’s ambition is to become a substantial, sustainable and strategically important exploration and mining business focused on Norway.
The Company was founded in November 2018, is headquartered in the UK and has a 100%-owned Norwegian subsidiary, Norge Mineraler AS.
For further information, please visit www.norgemining.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005833/en/
Contact information
Buchanan Communications
Mark Court / James Husband
+44 (0) 20 7466 5000
norgemining@buchanan.uk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
